150,000 Shares in Sera Prognostics, Inc. (NASDAQ:SERA) Bought by Perkins Capital Management Inc.

Key Points

• Perkins Capital Management Inc. acquired a new position in Sera Prognostics, purchasing 150,000 shares for approximately $522,000, representing 0.40% ownership of the company.
• Several large investors have increased their stakes in Sera Prognostics, with significant increases by Wells Fargo & Company at 55.2% and Charles Schwab Investment Management at 5.3% during the fourth quarter.
• In its latest earnings report, Sera Prognostics had a quarterly earnings per share of ($0.20), surpassing analysts' estimates, but reported a negative return on equity of 51.35% and negative net margin of 28,685.22%.

Perkins Capital Management Inc. purchased a new position in shares of Sera Prognostics, Inc. (NASDAQ:SERA - Free Report) in the first quarter, according to its most recent filing with the Securities & Exchange Commission. The fund purchased 150,000 shares of the company's stock, valued at approximately $522,000. Perkins Capital Management Inc. owned approximately 0.40% of Sera Prognostics at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also modified their holdings of the company. BNP Paribas Financial Markets acquired a new stake in Sera Prognostics in the 4th quarter worth about $28,000. Price T Rowe Associates Inc. MD purchased a new stake in Sera Prognostics during the fourth quarter worth approximately $93,000. Gotham Asset Management LLC purchased a new stake in Sera Prognostics during the fourth quarter worth approximately $96,000. Walleye Capital LLC purchased a new stake in Sera Prognostics during the fourth quarter worth approximately $98,000. Finally, Focus Partners Wealth purchased a new stake in Sera Prognostics during the fourth quarter worth approximately $102,000. 54.64% of the stock is currently owned by hedge funds and other institutional investors.

Sera Prognostics Price Performance

Sera Prognostics stock traded down $0.15 during midday trading on Thursday, hitting $2.73. 22,580 shares of the company were exchanged, compared to its average volume of 234,334. The company's fifty day moving average price is $2.29 and its 200-day moving average price is $3.44. Sera Prognostics, Inc. has a fifty-two week low of $1.37 and a fifty-two week high of $9.13. The company has a market cap of $102.65 million, a PE ratio of -2.90 and a beta of 0.99.

Sera Prognostics (NASDAQ:SERA - Get Free Report) last posted its quarterly earnings results on Wednesday, May 14th. The company reported ($0.20) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.24) by $0.04. The firm had revenue of $0.04 million for the quarter, compared to analysts' expectations of $0.06 million. Sera Prognostics had a negative net margin of 28,685.22% and a negative return on equity of 51.35%. On average, analysts expect that Sera Prognostics, Inc. will post -0.96 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Separately, Wall Street Zen upgraded shares of Sera Prognostics from a "sell" rating to a "hold" rating in a research note on Saturday, June 21st.

Insider Activity

In related news, CEO Zhenya Lindgardt sold 23,042 shares of the company's stock in a transaction that occurred on Monday, June 9th. The stock was sold at an average price of $1.43, for a total transaction of $32,950.06. Following the sale, the chief executive officer directly owned 844,209 shares of the company's stock, valued at approximately $1,207,218.87. This represents a 2.66% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Over the last quarter, insiders sold 67,848 shares of company stock worth $128,049. Corporate insiders own 13.50% of the company's stock.

Sera Prognostics Profile

Sera Prognostics, Inc, a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes in the United States. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies.